Close menu




September 23rd, 2022 | 11:28 CEST

Defence Therapeutics, Amazon, BioNTech - Innovative technologies for health

  • Biotechnology
  • Investments
  • Healthcare
Photo credits: pixabay.com

While WHO Director-General Tedros Adhanom Ghebreyesus sees the end of the Corona pandemic within reach, companies like BioNTech have more products in the pipeline to bring successful drugs to market. In order to ensure that this happens thoroughly and more quickly, Canadian company Defence Therapeutics is stepping up to shorten development cycles with a unique platform technology in oncology. Cancer has still not been eradicated. An end, however, is in sight for Amazon's in-house healthcare division. Amazon Care is closing its doors at the end of the year, but the Seattle-based corporation still cannot let go of the lucrative healthcare business...

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: DEFENCE THERAPEUTICS INC | CA24463V1013 , AMAZON.COM INC. DL-_01 | US0231351067 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:


    Defence Therapeutics - Platform technology in the fight against cancer

    Pharmaceutical industry insiders know that the shorter the development cycles for new drugs become, the faster there is revenue-generating growth potential through sales. It takes an average of 13 years to develop a drug. The average cost of developing a new innovative drug is up to EUR 2.6 billion. Especially in cancer treatment, it can therefore be too late for many patients until a new drug to relieve their symptoms receives its approval.

    In order to shorten this development time without compromising quality, the Canadian biotech company Defence Therapeutics offers an innovative platform technology specifically for oncology. "Accum" is the name of the platform that helps improve biologic drugs. It is used in the treatment of cancer and infectious diseases.

    Defence Therapeutics focuses on specialized cell nucleus research to solve a major problem in vaccines and antibody-drug conjugates (ADCs). When a target cell binds and internalizes an antigen or ADC, the complex becomes entrapped in small vesicles called endosomes. These endosomes eventually undergo a maturation phase until degradation. The entrapment of endosome lysosomes is often problematic and severely limits the efficacy of these types of therapies.

    Defence Therapeutics' Accum-Enhancer formulation improves intracellular delivery of biological therapeutics by bundling the process to increase therapeutic efficacy. Defence Therapeutics owns all rights and patents to the proprietary platform solution. Its unique technology can thus accelerate drug development against breast cancer, colorectal cancer, lymphoma and skin cancer (melanoma). The stock currently stands at EUR 1.24, analysts at Barron's issue a buy recommendation.

    Amazon - In-house care division closes down

    One of the world's largest and most successful platform technology operators is still Amazon. Also in Seattle, Amazon is trying its hand at the lucrative health sector. Just recently, Amazon talked about taking over the US telemedicine provider One Medical from San Francisco for USD 3.9 billion. One Medical operates 182 GP practices. Users can book virtual or in-person doctor treatments around the clock for a fee. One Medical also works with over 8,000 businesses whose employees can use the physician network. At the moment, the deal is under regulatory scrutiny.

    On the other hand, Amazon has closed its own Care division. Amazon Care, a telehealth startup from Amazon, was designed to help patients. According to ratings, reviews and patient interviews, the project has been a great success. However, that does not seem to be the case for the startup's actual customers - businesses. In an email to his staff, Neil Lindsay, Senior Vice President of Amazon Health, said that Amazon Care "is not a complete enough offering for the large enterprise customers we have been targeting".

    By the end of 2022, all ambitions to run its own patient record and physician service will expire. How does that fit together? In a memo to employees announcing the closure of Amazon Care, their executive indicated that the Company had not satisfied its enterprise customers washingtonpost.com/technology/2022/08/19/amazon-care-patient-safety-concerns. That could also be related to the tech giant's fast-paced, frugal approach to health care - an approach that former employees had previously criticized. Medical professionals hired to provide care were reported to sometimes have conflicts with the Company because of that approach, according to an Amazon spokesperson, who says the Company will "continue to work with industry stakeholders as part of this transition" even after Amazon Care closes.

    In healthcare, there is no shortcut to sequential steps, only a way to shorten the timeframes of each step, as Defence Therapeutics is doing.

    BioNTech - Israel launches vaccine with adapted Omicron compound

    With a presumed 329.5 million vaccine candidates down, the BioNTech share slides 8.6% this week. US President Joe Biden unceremoniously declared the Corona pandemic over. Health officials continue to view the current pandemic as a serious public health threat. Thousands of people are newly infected with the virus every day, which could lead to an increase in the number of infections in the coming fall and winter months.

    On Thursday, Israel started the vaccination campaign against the Omicron variant of the coronavirus. The vaccine doses from BioNTech and Pfizer are specifically tailored to the mutant variant, which has recently been very common in Israel. Israel led the world in vaccinating its 9.5 million residents against coronavirus last year. In a very short period of time, more than 60% of the population had been vaccinated with at least two doses of the Pfizer/BioNTech vaccine by the fall. More than 4.5 million Israelis have received a third dose of the vaccine, but only slightly more than 800,000 have received the fourth and final vaccination to date.

    Whether demand will increase with the adjusted vaccine remains in question. Israel has always taken a lead role as a nation in the fight against the coronavirus. While the World Health Organization has still classified COVID-19 as a pandemic, the end of the crisis appears to be in sight. Director-General Tedros Adhanom Ghebreyesus made the announcement last week. BioNTech has other drugs in the pipeline that will be used in the fight against cancer, among other things.


    Size and money are not decisive criteria for success in the healthcare industry. It requires relevant experience and expertise to understand and improve the complex interrelationships. Defence Therapeutics is an expert company. The team has deep experience in oncology and is well versed in drug development cycles. Those interested in learning more can ask Dr Moutih Rafei, Vice President R&D, questions at the Virtual II Forum on September 27. Click here to register for free. The proprietary platform solution enables the Company to shorten production runs without sacrificing quality, especially in oncology. Cancer is another milestone for BioNTech. In the pipeline lie products in the fight against prostate cancer, skin cancer and malignant ovarian cancer. Now that the Corona pandemic is coming to an end, the Company should be on the starting blocks with new diversified drugs. US platform giant Amazon, on the other hand, still seems to be searching for the golden nugget in the healthcare industry. Although its own service Amazon Care is closing, there is still interest in acquiring telemedicine provider One Medical.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Nico Popp on February 2nd, 2023 | 18:04 CET

    Bulging pipeline at BioNTech, Cardiol Therapeutics - what is the problem at Aurora Cannabis?

    • Biotechnology
    • Cannabis
    • Cancer

    He who heals is right. It is not quite that simple with active ingredients that are about to be approved. Drugs and vaccines must undergo extensive studies and, last but not least, have to prevail against the existing competition. We look at the pipelines of three hot stocks and venture a forecast: Where is the greatest potential for investors?

    Read

    Commented by Stefan Feulner on February 1st, 2023 | 20:29 CET

    BioNTech, Defence Therapeutics, PAION - All dams broken

    • Biotechnology

    High price fluctuations due to approvals or successful test results are more the norm than the rule in the biotechnology sector. It is common for smaller stocks, in particular, to multiply within a few days. For example, the shares of Ambrx Biopharma increased by a whopping 1,000% within just one day, while the German biotech hopeful PAION doubled in price within a week. The next candidates for above-average performances are already waiting in the wings.

    Read

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?

    Read